bioRxiv · 18 Nov 2026
A plasma proteomic atlas of rare genetic neurodevelopmental disorders reveals convergent molecular signatures, neurodegenerative overlap, and a cross-disorder severity index
Ricardo N Ramirez, Megan Aumann, Lindsay Wieczorek, Sasha Elmizadeh, Albert Misko, Yael Weiss, Stephanie Szobota, Berit Powers, Shruti Sasaki, Marco Rizzo, Smitha Jagadish, Mariana Laranjo, Nicole Davis, Jeremy Manry, Marie Elodie Cattin Messaoudi, Joerg Hipp, Rachael Hawtin, Brett Younginger, Nichol Miller, Kevin Wright, Grace Viggiano, Sarah Poliquin, Taylor Morris, Zollie Yavarow, Nicholas Aguilar, Ananya Terala, William Keener, Kristin Hatcher, Christopher Ricupero, Jennifer Bain, Elizabeth Berry Kravis, Jacqueline Harris, Natasha Ludwig, Angela Duong, Wayne Poon, Terry Jo V Bichell, Anna C Pfalzer
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Rare genetic neurodevelopmental disorders are individually too small for well-powered biomarker studies, and each is typically studied alone. We present a harmonized plasma proteomic resource that treats them together: over 10,000 proteins measured across 27 rare genetic neurodevelopmental disorders and unaffected family members, 26 of them with enough participants for differential abundance analysis, paired with standardized adaptive behaviour phenotypes and released with the full analysis pipeline. Aggregating across disorders makes shared biology visible that single-disorder studies cannot resolve. Genetically distinct disorders converge onto two proteomic clusters separated along a single dominant axis, distinguishing cytoskeletal and vesicle-trafficking proteins from metabolic and hepatic ones; the grouping is independent of gene function and of clinical classification, indicating convergence on shared downstream biology rather than gene-specific pathology. Epilepsy leaves a reproducible plasma signature detectable across disorders and largely independent of genotype, identifying candidate markers of seizure burden that are shared rather than syndrome specific. These proteomes also overlap those of adult neurodegenerative disease: most disorders are enriched against at least one signature of Alzheimer disease, Parkinson disease, frontotemporal dementia or amyotrophic lateral sclerosis, more often inversely than concordantly, placing early-life monogenic disorders on a shared axis with late-onset degeneration. A multivariate severity index built from plasma proteins tracks adaptive communication ability in disorders held out entirely from model training and distinguishes severity among individuals who share a diagnosis rather than only separating disorders from one another. Twenty-four of the prioritised cross-disorder proteins have a recorded drug interaction, several with agents already approved for other indications. Recruitment was concentrated at single sites for a subset of disorders, and results for those disorders are reported separately and descriptively throughout. Collectively, these findings support a shift from single-gene to pathway-based, cross-disorder trial strategies that leverage convergent biomarker panels and mechanistically informed, potentially repurposed interventions.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (0)
What it cites, from open citation data, with Crossref's record of each.